Christel Menet PhD

Christel joined Confo as CSO in 2016. She was one of the first chemists to join Galapagos and later advanced to Director of Medicinal Chemistry. She is the inventor of filgotinib (Jyseleca), commercialized for the treatment of moderate to severe active rheumatoid arthritis. Before Galapagos, Christel worked at Faust Pharmaceuticals (now Domain Therapeutics), a biotechnology company specializing in GPCR drug discovery. She is an inventor on over 25 patent applications and brings over 20 years of R&D experience to Confo. Christel completed a PhD in Organic Chemistry at the University of Manchester in the lab of Prof Jonathan Clayden.